Twist Bioscience Fiscal Q4 Revenues More Than Double

Nov 23, 2020

|

NEW YORK – Twist Bioscience reported on Monday morning that revenues for its fiscal fourth quarter 2020 more than doubled year over year.

For the three months ended Sept. 30, 2020, the firm reported revenues of $32.4 million compared to $15.7 million in the year-ago period. It beat analysts' average revenue estimate of $22.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

A Few, as Expected

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

For the Unknown Soldiers

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Prep for the Next One

Vox and Nature discuss the importance of preparing for the next pandemic.

Nature Papers Compare CtDNA Assays, Examine Lettuce Domestication, More

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.

Menu

Twist Bioscience Fiscal Q4 Revenues More Than Double

To read the full story....

Breaking News

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

Wellcome Leap Launches $55M Program to Develop Disease-Specific Tissue Profiling Platforms

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Tabula Rasa Healthcare, OneOme Form Precision Prescribing Alliance

Neanderthal Population Replacement Detected Using Spanish Cave Sediments

OncoDNA, Institut Curie Partner on Liquid Biopsy Research in Head and Neck Cancer

The Scan

A Few, as Expected

For the Unknown Soldiers

Prep for the Next One

Nature Papers Compare CtDNA Assays, Examine Lettuce Domestication, More

What's Popular?

Thermo Fisher Scientific to Acquire Contract Research Organization PPD for $17.4B

Benchling Raises $200M in Series E Funding Round

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Cancer Dx Firm C2i Genomics Raises $100M in Financing

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Sponsorships